TITLE PAGE Title Decompensated hepatitis C virus-related cirrhosis delisted from liver transplantation after successful sofosbuvir-based treatment Running title HCV cirrhosis delisting after sofosbuvir treatment Authors Isaac RUIZ, MD, MSc1 Cyrille FERAY, MD, PhD1,2 Jean-Michel PAWLOTSKY, MD, PhD1,3 Christophe HEZODE, MD, PhD1,2 1
INSERM U955, Hôpital Henri Mondor, Créteil, France
2
Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, AP-HP,
Université Paris-Est, Créteil, France 3
National Reference Center for Viral Hepatitis B, C and Delta, Department of
Virology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France Keywords Decompensated cirrhosis, Hepatitis C virus, liver transplantation, sofosbuvir.
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi: 10.1002/lt.24051 This article is protected by copyright. All rights reserved.
Liver Transplantation
Page 2 of 6
2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
FOOTNOTE PAGE 1. List of Abbreviations ALT: Alanine aminotransferase AST: Aspartate aminotransferase HCV: Hepatitis C virus LT: Liver transplantation MELD: Model For End-Stage Liver Disease PI: Protease inhibitors PT: Prothrombin Time 2. Grants and financial support No specific funding for this study. 3. Conflicts of interest Isaac Ruiz has nothing to disclose. Cyrille Feray has nothing to disclose. Jean-Michel Pawlotsky has received research grants from Gilead Sciences. He has served as an advisor for Abbott, Abbvie, Achillion, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Janssen Therapeutics, Merck, Novartis, and Roche. Christophe Hézode has been a clinical investigator, speaker and/or consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp & Dohme, and Roche. 4. Corresponding author Pr Christophe Hézode, MD, PhD Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, 51, avenue du maréchal de Lattre de Tassigny, 94010 Créteil Cedex, France. E-mail address: [email protected] Tel: +33 1 49 81 23 25 Fax: +33 1 49 81 23 52
John Wiley & Sons, Inc. This article is protected by copyright. All rights reserved.
LT-14-560
Page 3 of 6
Liver Transplantation
3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
LETTERS FROM THE FRONTLINE Decompensated cirrhosis related to chronic hepatitis C virus (HCV) accounts for the majority of liver transplantations (LT) in western countries. Recurrent HCV infection is universal in transplanted patients with detectable HCV RNA at the time of LT and leads to rapidly aggravating liver graft function in a substantial number of them (1). Studies in patients with compensated cirrhosis with portal hypertension and poor liver function (platelet count ≤100,000/mm3 and serum albumin
INSERM U955, Hôpital Henri Mondor, Créteil, France
2
Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, AP-HP,
Université Paris-Est, Créteil, France 3
National Reference Center for Viral Hepatitis B, C and Delta, Department of
Virology, Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France Keywords Decompensated cirrhosis, Hepatitis C virus, liver transplantation, sofosbuvir.
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi: 10.1002/lt.24051 This article is protected by copyright. All rights reserved.
Liver Transplantation
Page 2 of 6
2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
FOOTNOTE PAGE 1. List of Abbreviations ALT: Alanine aminotransferase AST: Aspartate aminotransferase HCV: Hepatitis C virus LT: Liver transplantation MELD: Model For End-Stage Liver Disease PI: Protease inhibitors PT: Prothrombin Time 2. Grants and financial support No specific funding for this study. 3. Conflicts of interest Isaac Ruiz has nothing to disclose. Cyrille Feray has nothing to disclose. Jean-Michel Pawlotsky has received research grants from Gilead Sciences. He has served as an advisor for Abbott, Abbvie, Achillion, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Janssen Therapeutics, Merck, Novartis, and Roche. Christophe Hézode has been a clinical investigator, speaker and/or consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck Sharp & Dohme, and Roche. 4. Corresponding author Pr Christophe Hézode, MD, PhD Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, 51, avenue du maréchal de Lattre de Tassigny, 94010 Créteil Cedex, France. E-mail address: [email protected] Tel: +33 1 49 81 23 25 Fax: +33 1 49 81 23 52
John Wiley & Sons, Inc. This article is protected by copyright. All rights reserved.
LT-14-560
Page 3 of 6
Liver Transplantation
3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
LETTERS FROM THE FRONTLINE Decompensated cirrhosis related to chronic hepatitis C virus (HCV) accounts for the majority of liver transplantations (LT) in western countries. Recurrent HCV infection is universal in transplanted patients with detectable HCV RNA at the time of LT and leads to rapidly aggravating liver graft function in a substantial number of them (1). Studies in patients with compensated cirrhosis with portal hypertension and poor liver function (platelet count ≤100,000/mm3 and serum albumin
